HelpAcademyLoginJoin us as a Member

Competitive landscape

Drugs aimed at the same indication, from approved to preclinical.

49 drugs for “Small-cell Lung Cancer”

Approved 13

  • CemiplimabREGENERON PHARMACEUTICALS, INC.Advanced Non-Small Cell Lung Cancer
  • CosibelimabCheckpoint Therapeutics, Inc.Metastatic Non-squamous Non Small Cell Lung Cancer
  • DacomitinibPFIZER INCNon-Small Cell Lung Cancer; Non-small Cell Lung Cancer With EGFR-Activating Mutations
  • DinutuximabUNITED THERAPEUTICS CorpSmall Cell Lung Cancer
  • DurvalumabASTRAZENECA PLCNon-Small Cell Lung Cancer
  • NecitumumabELI LILLY & CoNon Small Cell Lung Cancer
  • OsimertinibASTRAZENECA PLCNon-small Cell Lung Cancer
  • RetifanlimabINCYTE CORPMetastatic Nonsquamous Non-Small Cell Lung Cancer; Metastatic Squamous Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer
  • SelpercatinibELI LILLY & CoNon-Small Cell Lung Cancer
  • SelumetinibASTRAZENECA PLCLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
  • SotorasibAMGEN INCNon-Small Cell Lung Cancer (NSCLC)
  • TarlatamabAMGEN INCSmall Cell Lung Cancer; Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer
  • Telisotuzumab vedotinAbbVie Inc.Non Small Cell Lung Cancer; Non-Small Cell Lung Cancer

Phase 3 25

  • IvonescimabSummit Therapeutics Inc.Non-Small Cell Lung Cancer · next catalyst 14 Nov 2026
  • ABBV-1480AbbVie Inc.Non-Small Cell Lung Cancer
  • ABBV-706AbbVie Inc.Small Cell Lung Cancer
  • Aglatimagene besadenovecCandel Therapeutics, Inc.Non-squamous, Non-Small Cell Lung Cancer
  • AK112Summit Therapeutics Inc.Non-Squamous Non-small Cell Lung Cancer
  • AmrubicinAbbVie Inc.Small Cell Lung Cancer
  • AZD9291ASTRAZENECA PLCLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
  • BMS-986489BRISTOL MYERS SQUIBB COExtensive-Stage Small Cell Lung Cancer
  • CalderasibMerck & Co., Inc.Non-small Cell Lung Cancer
  • CeralasertibASTRAZENECA PLCAdvanced or Metastatic Non-Small Cell Lung Cancer
  • Eftilagimod alfaIMMUTEP LtdAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
  • FianlimabREGENERON PHARMACEUTICALS, INC.Advanced Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer
  • FirmonertinibArriVent BioPharma, Inc.Advanced Non-Small-Cell Lung Cancer; Metastatic Non-Small-Cell Lung Cancer
  • FurmonertinibArriVent BioPharma, Inc.Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
  • IntismeranMerck & Co., Inc.Non-small Cell Lung Cancer
  • Intismeran autogeneMerck & Co., Inc.Non-small Cell Lung Cancer
  • JDQ443NOVARTIS AGNon-Small Cell Lung Cancer
  • MK-3475AMerck & Co., Inc.Non-small Cell Lung Cancer
  • MonalizumabASTRAZENECA PLCNon-Small Cell Lung Cancer
  • MRTX849Mirati Therapeutics, Inc.Advanced Non Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer
  • NeladalkibNuvalent, Inc.Non-small Cell Lung Cancer
  • Pembrolizumab berahyaluronidase alfaMerck & Co., Inc.Non-small Cell Lung Cancer
  • PumitamigBRISTOL MYERS SQUIBB CONon-Small Cell Lung Cancer (NSCLC)
  • REGN2810REGENERON PHARMACEUTICALS, INC.Non-small Cell Lung Cancer
  • RilvegostomigASTRAZENECA PLCNon-small Cell Lung Cancer

Phase 2/3 4

  • BMS-986504BRISTOL MYERS SQUIBB COMetastatic Non-small Cell Lung Cancer With MTAP Deletion
  • BudigalimabAbbVie Inc.Non-Small Cell Lung Cancer
  • EIK1001Eikon Therapeutics, Inc.Non Small Cell Lung Cancer (Squamous or Non Squamous)
  • LivmoniplimabAbbVie Inc.Non-Small Cell Lung Cancer

Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.